A Phase 1, Open-label, Dose Escalation Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 04 May 2017
At a glance
- Drugs Oprozomib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Onyx Pharmaceuticals
- 22 Aug 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 22 Aug 2012 Planned end date changed from 1 Jul 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 06 Jun 2012 Interim results have been reported at ASCO 2012.